Ananth Sridhar
COO
Ananth Sridhar is chief operating officer of BridgeBio’s cardiorenal programs, where he leads two of the company’s most advanced therapies, including recently approved Attruby™ (acoramidis) and encaleret, an investigational therapy for ADH1 and chronic hypoparathyroidism. Since joining BridgeBio in 2018, he has helped advance multiple therapies for patients with unmet needs. Previously, he held roles of increasing responsibility at Regeneron, contributing to the development of Praluent®, Dupixent®, and Kevzara®. Ananth earned his B.S. in Chemical Engineering from Stanford University and M.B.A. from Harvard Business School.